(Q24240981)

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Added benefits of drospirenone for compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Progesterone for premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Twenty micrograms vs. >20 microg estrogen oral contraceptives for contraception: systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Combination contraceptives: effects on weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Prevalence of sexual abuse history in a sample of women seeking treatment for premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: a clinical primer for practitioners

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Oral contraceptives and mood in women with and without premenstrual dysphoria: a theoretical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

The development of a menstrual distress questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Drospirenone, a progestogen with antimineralocorticoid properties: a short review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Psychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

ICH E9 guideline 'Statistical principles for clinical trials': a case study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Factor structure of the Modified Moos Menstrual Distress Questionnaire: assessment of prospectively reported follicular, menstrual and premenstrual symptomatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Allocation concealment in randomised trials: defending against deciphering

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Sample size slippages in randomised trials: exclusions and the lost and wayward

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

New progestagens for contraceptive use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Effect Measures for Meta-Analysis of Trials with Binary Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

Daily Record of Severity of Problems (DRSP): reliability and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

7 January 2021

An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

7 January 2021

Cognitive therapy for premenstrual syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

7 January 2021

A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

7 January 2021

Treatment of premenstrual syndrome by spironolactone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

7 January 2021

Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006586.PUB3

7 January 2021